A peer-reviewed journal that offers evidence-based clinical information and continuing education for dentists.

WHO Adds Interleukin-6 Receptor Blockers to COVID-19 Treatment List


Individuals who become gravely ill with COVID-19 often experience an overzealous immune response, worsening their condition. The use of interleukin-6 receptor blockers, such as tocilizumab and sarilumab, can quell this overreaction, according to a meta-analysis conducted by the World Health Organization (WHO). As such, the WHO issued a new guideline that recommends the use of these medications, particularly in combination with corticosteroids, in the treatment of severe COVID-19 illness. The meta-analysis, which included more than 10,000 patients, found that the risk of death among those taking interleukin-6 receptor blockers was 13% lower than those who did not receive the medication regimen. The WHO is requesting that manufacturers of such medications increase their production as soon as possible. Click here to read more.

Leave A Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy